002550 千红制药
已收盘 05-28 15:00:00
资讯
新帖
简况
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
证券之星 · 05-27 11:36
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
证券之星 · 05-25
千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验
千红制药：公司可转债项目已获深交所受理
证券之星 · 05-25
千红制药：公司可转债项目已获深交所受理
千红制药：公司可转债项目于2026年2月12日收到审核问询函
证券之星 · 05-25
千红制药：公司可转债项目于2026年2月12日收到审核问询函
股市必读：千红制药（002550）5月22日董秘有最新回复
证券之星 · 05-25
股市必读：千红制药（002550）5月22日董秘有最新回复
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
市场资讯 · 05-24
转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴
股市必读：千红制药（002550）5月20日董秘有最新回复
证券之星 · 05-21
股市必读：千红制药（002550）5月20日董秘有最新回复
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
证券之星 · 05-20
转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
证券之星 · 05-20
千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中
股市必读：千红制药（002550）5月19日董秘有最新回复
证券之星 · 05-20
股市必读：千红制药（002550）5月19日董秘有最新回复
股市必读：千红制药（002550）5月18日董秘有最新回复
证券之星 · 05-19
股市必读：千红制药（002550）5月18日董秘有最新回复
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
证券之星 · 05-18
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一
证券之星 · 05-18
千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一
千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关
证券之星 · 05-18
千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关
千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订
证券之星 · 05-18
千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
证券之星 · 05-14
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
股市必读：千红制药（002550）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：千红制药（002550）5月8日董秘有最新回复
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 05-08
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 05-08
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
东海证券：给予千红制药买入评级
证券之星 · 05-08
东海证券：给予千红制药买入评级
加载更多
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":6.29,"timestamp":1779951801000,"preClose":6.37,"halted":0,"volume":12670500,"delay":0,"changeRate":-0.0126,"floatShares":941000000,"shares":1280000000,"eps":0.2523,"marketStatus":"已收盘","change":-0.08,"latestTime":"05-28 15:00:00","open":6.36,"high":6.38,"low":6.2,"amount":79501200,"amplitude":0.0283,"askPrice":6.31,"askSize":297,"bidPrice":6.29,"bidSize":1278,"shortable":0,"etf":0,"ttmEps":0.2523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780018200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.37,"symbolType":"stock","openAndCloseTimeList":[[1779931800000,1779939000000],[1779944400000,1779951600000]],"highLimit":7.01,"lowLimit":5.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":2.86,"roa":"--","peRate":24.930638,"roe":"3.03%","epsLYR":0.32,"committee":0.172163,"marketValue":8050000000,"turnoverRate":0.0135,"status":1,"floatMarketCap":5920000000},"requestUrl":"/m/hq/s/002550/","defaultTab":"news","newsList":[{"id":"2638735555","title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2638735555","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638735555?lang=zh_cn&edition=full","pubTime":"2026-05-27 11:36","pubTimestamp":1779853004,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问:公司收到交易所关于申请发行可转换债券问询函是属于重大事项？为什么没有发布收到该问询函的公告？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据相关监管要求进行了科学合理的工作推进安排并及时公告。感谢您的关注。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700019949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535038","title":"千红制药：公司创新药项目均严格按照国家药品注册法规要求推进临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535038?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697093,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请正面回答公司可转债申报阶段是否知道创新药106要进行增补验证？千红制药回复：尊敬的投资者，您好，公司创新药项目均严格按照国家药品注册法规要求推进临床试验，相关进展将依法依规履行披露义务，感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","002550","BK1161","06978","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638535033","title":"千红制药：公司可转债项目已获深交所受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2638535033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638535033?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697093,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：公司的可转换债券审核进度是否异常千红制药回复：尊敬的投资者，您好，公司可转债项目已获深交所受理，并于2026年2月12日收到审核问询函，公司已于3月10日完成回复并公告。目前该项目正在有序推进中，后续进展将依法依规及时披露。感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638350805","title":"千红制药：公司可转债项目于2026年2月12日收到审核问询函","url":"https://stock-news.laohu8.com/highlight/detail?id=2638350805","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638350805?lang=zh_cn&edition=full","pubTime":"2026-05-25 16:18","pubTimestamp":1779697090,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司近期有没有收到交易所二次问询函？千红制药回复：尊敬的投资者，您好，公司可转债项目于2026年2月12日收到审核问询函，公司已于3月10日完成回复并公告。目前该项目正在有序推进中，后续进展将依法依规及时披露。感谢您的关注。以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500021649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638304665","title":"股市必读：千红制药（002550）5月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2638304665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638304665?lang=zh_cn&edition=full","pubTime":"2026-05-25 01:56","pubTimestamp":1779645372,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，千红制药报收于6.59元，上涨1.85%，换手率1.3%，成交量12.27万手，成交额8019.92万元。来自公司公告汇总：千红制药将于2026年5月29日实施除权除息，每10股派发现金红利1.5元（含税）。公司公告汇总千红制药：2025年度权益分派实施公告常州千红生化制药股份有限公司2025年度权益分派方案为：以公司总股本1,279,800,000股剔除回购专用账户中库存股18,000,000股后的1,261,800,000股为基数，向全体股东每10股派发现金红利1.5元（含税）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637491308","title":"转型阵痛中的千红制药：肝素原料药周期冲击业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2637491308","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637491308?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:00","pubTimestamp":1779606000,"startTime":"0","endTime":"0","summary":" 作为国内少数涵盖肝素全产业链的生化药企，千红制药在经历了2022年的营收峰值后，连续两年下滑，2025年借低基数实现微弱反弹，却远未恢复至历史高点。进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。 证券之星注意到，被千红制药寄予厚望的创新药“第二曲线”仍处于临床阶段，距离商业化贡献业绩尚需时日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2026-05-24/doc-inhyytnm5942974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","159992","002550","BK1161","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878700","title":"股市必读：千红制药（002550）5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637878700?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:14","pubTimestamp":1779308092,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，千红制药报收于6.57元，下跌2.67%，换手率1.84%，成交量17.36万手，成交额1.14亿元。董秘： 尊敬的投资者，您好，根据公司2025年11月披露的可转债项目相关公告，公司原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一，该项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100004952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636581718","title":"转型阵痛中的千红制药：肝素原料药周期冲击一季度业绩，创新药远水难解近渴","url":"https://stock-news.laohu8.com/highlight/detail?id=2636581718","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636581718?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:00","pubTimestamp":1779267644,"startTime":"0","endTime":"0","summary":"进入2026年一季度，出口肝素原料药遭遇全球需求疲软与合同发货周期的双重打击，公司营收与归属净利润再度双双大幅下挫。2023年财报中，千红制药曾坦言，肝素原料药面临下游企业去库存、需求大幅下滑导致出口价格与数量均显著下降，行业整体受到较大冲击。对于肝素主业与创新药业务之间的战略重心如何平衡，千红制药回应称，未来将加大重大创新药物的研发与上市节奏，使之成为公司业务增长的新的战略核心。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026052000030426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","002550","BK1161","BK1574","BK0239","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636892475","title":"千红制药：公司创新药项目均处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2636892475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636892475?lang=zh_cn&edition=full","pubTime":"2026-05-20 11:36","pubTimestamp":1779248185,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月20日在投资者关系平台上答复投资者关心的问题。公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000019084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","06978","BK1574","159992","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636866889","title":"股市必读：千红制药（002550）5月19日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636866889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636866889?lang=zh_cn&edition=full","pubTime":"2026-05-20 02:05","pubTimestamp":1779213913,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘，千红制药报收于6.75元，下跌0.3%，换手率0.94%，成交量8.85万手，成交额5971.34万元。董秘最新回复投资者： 董秘您好，贵公司发布公告相当马虎，5月14日为周四，材料为周三。当日关注点来自交易信息汇总：主力资金5月19日净流出1038.47万元，显示主力短期态度偏空。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000001633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636008542","title":"股市必读：千红制药（002550）5月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636008542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636008542?lang=zh_cn&edition=full","pubTime":"2026-05-19 01:15","pubTimestamp":1779124511,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，千红制药报收于6.77元，下跌2.17%，换手率1.29%，成交量12.17万手，成交额8268.64万元。董秘： 尊敬的投资者，您好，公司创新药相关进展需严格遵循法规披露要求，公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订，具体修订内容详见公司相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900001852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636760047","title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2636760047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636760047?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:06","pubTimestamp":1779087976,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：按规定公司收到问询函是要在2天内公告的！为什么公司拖了差不多一个月股民才在回复中知道此事？请详细解答该疑问？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据监管要求进行了科学合理的工作安排并及时公告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636047737","title":"千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636047737","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636047737?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:03","pubTimestamp":1779087792,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月18日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，根据公司2025年11月披露的可转债项目相关公告，公司原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一，目前该项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636465860","title":"千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关","url":"https://stock-news.laohu8.com/highlight/detail?id=2636465860","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636465860?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:36","pubTimestamp":1779075388,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问贵公司与中科院生物物理研究生共建的“危重症靶向蛋白药联合实验室”主要研发内容有哪些？千红制药回复：尊敬的投资者，您好，公司与中国科学院生物物理研究所大分子国家重点实验室合作共建联合实验室，主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800012790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046386","title":"千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046386?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:30","pubTimestamp":1779075032,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：王董为什么不解释清楚同一个创新药却是两个临床试验代号两种自相矛盾的临床进度？还有公司是否确定2025年的可转换债券项目是2024年版本的修订版？千红制药回复：尊敬的投资者，您好，公司创新药相关进展需严格遵循法规披露要求，公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订，具体修订内容详见公司相关公告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800012378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746638","title":"千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746638","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635746638?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:47","pubTimestamp":1778770030,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，千红制药报收于6.97元，较前一交易日下跌1.13%，最新总市值为89.2亿元。该股当日开盘7.09元，最高7.09元，最低6.96元，成交额达8452.93万元，换手率为1.28%。近日，千红制药发布《2025年度股东会决议公告》。公告显示，公司于2026年5月14日召开2025年度股东会，会议由董事会召集，董事长王耀方主持，采用现场与网络投票相结合方式召开。出席会议的股东及授权代表共513名，代表有表决权股份总数的41.1970%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426396","title":"股市必读：千红制药（002550）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634426396?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:48","pubTimestamp":1778438894,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.25%，成交量11.77万手，成交额8346.92万元。当日关注点来自交易信息汇总：5月8日主力资金净流出608.31万元，散户资金净流入720.8万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633106487","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633106487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633106487?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:07","pubTimestamp":1778224034,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月08日在投资者关系平台上答复投资者关心的问题。为什么公司的信披那么不透明甚至隐瞒呢？公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248729","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633248729?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:04","pubTimestamp":1778223862,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问宁独董:公司在2025年中期报告关于106创新药进展的描述中明确写道该药已完成期临床，但现实是该药却要做期b的补充临床验证，这是不是夸大临床进度误导投资者？作为独立董事有没有尽职做到监督作用？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101326","title":"东海证券：给予千红制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633101326?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:35","pubTimestamp":1778200535,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,付婷近期对千红制药进行研究并发布了研究报告《公司简评报告：业绩短期放缓，期待创新转型成果》，给予千红制药买入评级。河南千牧已正式投产，为公司提供充足的肝素上游原材料，湖北千红药用酶原料药基地已竣工，支撑胰激肽原酶、弹性蛋白酶等核心制剂规模化生产。QHRD211注射液是重组人生长激素，目前已完成II期临床患者入组。公司主营业务整体稳健，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800007569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","161027"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779995020391,"stockEarnings":[{"period":"1week","weight":-0.0278},{"period":"1month","weight":-0.1153},{"period":"3month","weight":-0.1926},{"period":"6month","weight":-0.2539},{"period":"1year","weight":-0.0954},{"period":"ytd","weight":-0.1997}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0049},{"period":"3month","weight":-0.0154},{"period":"6month","weight":0.054},{"period":"1year","weight":0.2272},{"period":"ytd","weight":0.0327}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74524人(较上一季度增加2.43%)","perCapita":"12630股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}